A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 21, 2025

Primary Completion Date

January 15, 2029

Study Completion Date

May 30, 2029

Conditions

Solid Tumors

Interventions

DRUG

BI 1831169

DRUG

nivolumab

Trial Locations (1)

National Cancer Center Hospital East, Chiba, Kashiwa